Daiichi Sankyo Company, Limited · TSE:4568

Daiichi Sankyo — Q3 FY2018 Earnings Presentation

37 slides from Daiichi Sankyo's earnings presentation, Jan 31, 2019

  1. Slide 1: FY2018 Q3 Financial Results Presentation

    FY2018 Q3 Financial Results Presentation DAIICHI SANKYO CO., LTD Toshiaki Sai Executive Vice President and CFO January 31, 2019

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements Management strategies and plans, financial forecasts, future projections and policies, and R&D information that Daiichi Sankyo discloses in this material are all classified as Daiichi Sankyo’s future prospects. These forward looking statements were determined by Daiichi Sa

  3. Slide 3: Agenda

    Agenda  FY2018 Q3 Financial Results  Business Update  Edoxaban  Regional Value  Optimizing Supply Chain  R&D Update 3

  4. Slide 4: FY2018 Q3 Financial Results

    FY2018 Q3 Financial Results 4

  5. Slide 5: Overview of FY2018 Q3 Results

    Overview of FY2018 Q3 Results (Bn JPY) FY2017 Q3 YTD FY2018 Q3 YTD YoY Results Results -5.1% Revenue 741.0 703.1 -38.0 Cost of Sales 255.5 264.9 +9.5 SG&A Expenses 216.7 198.5 -18.2 R&D Expenses 175.6 142.6 -33.0 +4.1% Operating Profit 93.2 97.1 +3.9 Profit before Tax 97.7 98.0 +0.2 Profit attributa

  6. Slide 6: Revenue

    Revenue Decreased by 38.0 Bn JPY (Decreased by 36.5 Bn JPY excl. forex impact) (Bn JPY) Positive Factors Negative Factors FY2017 Results Japan 741.0 Lixiana +14.6 Olmetec -28.5 Japan Pralia +3.7 Nexium -9.0 (incl. vaccines, 24.9 Inavir -4.8 OTC-related) Loxonin -4.7 (Incl. impact of price revision i

  7. Slide 7: Operating Profit

    Operating Profit Increased by 3.9 Bn JPY (Decreased by 23.4 Bn JPY excl. forex impact and special items) FY2017 Results 93.2 増益 減益 (Bn JPY) Revenue -38.0 Revenue 38.0 incl. forex impact of -1.5 Cost of Sales 3.8 Cost of Sales +3.8 (Cost increased) Product mix due to impact of olmesartan LOE SG&A Exp

  8. Slide 8: Special Items

    Special Items (Bn JPY) FY2017 Q3 YTD FY2018 Q3 YTD YoY Results Results Cost of Sales Gain on sales of fixed assets -6.1 +6.1 SG&A Expenses Gain on sales of fixed assets -3.5 -3.5 R&D Expenses Impairment loss (Intangible) 30.2 -30.2 Total 24.1 -3.5 -27.6 - : Cost decreased items * No items booked in

  9. Slide 9: Profit Attributable to Owners of the Company

    Profit Attributable to Owners of the Company Increased by 6.2 Bn JPY FY2017 Results 72.6 (Bn JPY) Financial Income/ +3.7 (Cost increased) Operating Profit 3.9 Expenses etc. Deterioration of forex gains/ losses Financial Income/ Expenses etc. 3.7 Income Taxes etc. -6.5 (Cost decreased) Impact of the

  10. Slide 10: Revenue: Major Business Units (incl. Forex Impact)

    Revenue: Major Business Units (incl. Forex Impact) (Bn JPY) FY2017 FY2018 Q3 YTD Q3 YTD YoY Results Results Japan 418.1 395.7 -22.4 Daiichi Sankyo Healthcare 56.6 52.9 -3.6 Daiichi Sankyo, Inc. 64.1 28.6 -35.5 Olmesartan 17.4 7.9 -9.4 Welchol 29.3 11.0 -18.3 Effient 10.1 2.4 -7.7 Savaysa 1.6 1.6 +0.

  11. Slide 11: Revenue: Major Products in Japan

    Revenue: Major Products in Japan (Bn JPY) FY2017 FY2018 Q3 YTD Q3 YTD YoY Results Results Nexium ulcer treatment 70.0 61.0 -9.0 Lixiana anticoagulant 34.7 49.3 +14.6 Alzheimer’s disease Memary treatment 38.1 39.5 +1.4 Loxonin anti-inflammatory analgesic 29.0 24.3 -4.7 treatment for osteoporosis/ Pra

  12. Slide 12: Edoxaban

    eee pase Edoxaban 12

  13. Slide 13: Lixiana: Growth in Japan

    Lixiana: Growth in Japan Sales Lixiana reached No.1 sales share at FY2018 Q3 (%) 50 40 31.9% 30 30.9% 20 Lixiana Product A 10 Product B Product C 0 Copyright © 2019 IQVIA. Calculated based on JPM FY2014 Q1 - FY2018 Q3 Reprinted with permission 13

  14. Slide 14: Edoxaban: Growth in Each Country

    Edoxaban: Growth in Each Country Volume  Steady growth in each country  Approved in China (Dec. 2018) 30% 26.0% S. Korea 25% 25.4% Japan 20% 15.3% Taiwan 14.4% Belgium 15% 13.8% Germany 11.4% Italy 10% 11.0% Spain 5% 4.9% UK 0.3% USA 0% Brazil: Launched in Aug. 2018 Copyright © 2019 IQVIA. China:

  15. Slide 15: Regional Value

    eee pase Regional Value 15

  16. Slide 16: Regional Value Products

    Regional Value Products Aim to have enriched ”regional value products” aligned with regional business strategy in addition to ”global products” such as edoxaban and new oncology products toward 2025 Vision 16

  17. Slide 17: Enrichment of Regional Value Products

    Enrichment of Regional Value Products Global products:Edoxaban, oncology, etc. Europe North Japan America ASCA* bempedoic acid & combination tablet Nexium Injectafer Cravit Memary Venofer Asmeton Pralia Movantik Ranmark Tenelia Tarlige Minnebro Vimpat New products *ASCA: Asia, South & Central Americ

  18. Slide 18: Japan: New Products Approval and Additional Approval for Existing Products

    Japan: New Products Approval and Additional Approval for Existing Products  Tarlige (mirogabalin): Approved in Jan. 2019  MOA: α2δ ligand  Indication: peripheral neuropathic pain  Minnebro (esaxerenone): Approved in Jan. 2019  MOA: mineralocorticoid blocker  Indication: hypertension  Vimpat (

  19. Slide 19: Europe: In-licensed LDL-C Lowering Drug

    Europe: In-licensed LDL-C Lowering Drug  Originator: Esperion Therapeutics, Inc.  Licensing Agreement  bempedoic acid and bempedoic acid / ezetimibe combination tablet  MOA : ACL (ATP citrate lyase) inhibitor (First-in-class)  Route, dosage : Oral, once-daily  Territory : Europe  Role and res

  20. Slide 20: Optimizing Supply Chain

    Optimizing Supply Chain 20

  21. Slide 21: Optimizing SC

    Optimizing SC Future oriented SC structure transformation Future  Multiple, smaller volume Transformation medicines Until now  Large molecule compounds  Mass-produced products toward  Injectable formulations  Small molecule compounds the future  Solid formulations FY2015 Transfer of Akita Plan

  22. Slide 22: Takatsuki Plant Transfer

    Takatsuki Plant Transfer  Transferee:  Employees: continue to be employed by the transferee  Products: continue to be produced and stably supplied at the Takatsuki Plant  Transfer Date: Oct. 1st ,2019  Compensation: JPY 37.6 Bn  The net assets of the Takatsuki Plant  The book value including

  23. Slide 23: Reference: Production Sites (as of Oct. 2019)

    Reference: Production Sites (as of Oct. 2019) Japan 13 Sites Formulation Formulation / packaging API / packaging API Daiichi Sankyo Daiichi Sankyo Daiichi Sankyo Chemical Propharma Biotech* Pharma  Hiratsuka  Onahama  Kitamoto  Tatebayashi  Odawara US/EU/ASCA Formulation Formulation Formulation

  24. Slide 24: R&D Update

    eee pase R&D Update 24

  25. Slide 25: R&D Investment Focus and Efficiency

    R&D Investment Focus and Efficiency Prioritize projects in order to invest selectively in oncology, especially in ADC & AML/Hem Franchises and Breakthrough Science On-going Clinical studies* Major Projects Invest selectivity JAN 2018 JAN 2019 in oncology, DS-8201 3 9 especially in ADC franchise ADC

  26. Slide 26: List of Compounds for Out-Licensing

    List of Compounds for Out-Licensing Accelerate out-licensing activity and choose additional candidates  DS-5010 (selective RET inhibitor)  Out-licensed to Boston Pharmaceuticals Inc. (AUG 2017)  DS-6051 (NTRK/ROS1 inhibitor)  Out-licensed to AnHeart (DEC 2018) List of Out-licensing Projects Phas

  27. Slide 27: DS Advancing in Regenerative Medicine / Cell Therapy

    DS Advancing in Regenerative Medicine / Cell Therapy  Activities within the company until today  Strengthen DS RD structure (established Cell Therapy Lab.)  Explore compounds through alliances and move forward to commercialization Development Status Program Indications Partners Discovery Pre-clin

  28. Slide 28: Open Innovation Research on iPS-β cell

    Open Innovation Research on iPS-β cell Treatments of Type 1 diabetes Insulin injection Islet transplant iPS-β Separate Transplant iPS-β islet only cells by device Liver Pancreas Extract Infuse to liver Alternative treatment to Organ donor Type 1 diabetes patient insulin injection and islet transplan

  29. Slide 29: Next Data Point until ASCO 2019

    Next Data Point until ASCO 2019  DS-8201: Decision for early BLA submission in FY2018 Q4~  ASCO 2019 (May 31 ~ June 4, 2019)  U3-1402: P1 NSCLC dose escalation part is planned  DS-1062: P1 NSCLC dose escalation part is planned  Quizartinib: US PDUFA May 25, 2019 29

  30. Slide 30: Appendix

    Appendix - R&D Milestone Events - Major R&D Pipeline - Out-licensing Projects - DS-8201 presentation at Scientific Conference - Abbreviations 30

  31. Slide 31: FY2018 R&D Milestone Events

    FY2018 R&D Milestone Events As of Jan 2019 FY2018 FY2019 Project Study / Indication Q1 Q2 Q3 Q4 Q1~ P1: multiple tumors Enroll completed P2 pivotal: BC (HER2 positive Post T-DM1) Enroll completed P3: BC (HER2 positive Post T-DM1 vs Phys Choice) Study started P3: BC (HER2 positive vs T-DM1) Study sta

  32. Slide 32: Major R&D Pipeline (Oncology)

    Major R&D Pipeline (Oncology) As of Jan 2019 Generic Name/Project Code Number Stage Target indication Region (Class) Phase 1 Phase 2 Phase 3 NDA/BLA BC (HER2 positive post T-DM1) JP/US/EU/Asia ★ BC (HER2 positive vs. T-DM1) JP/US/EU/Asia DS-8201 (Anti-HER2 ADC) BC (HER2 low) JP/US/EU/Asia ADC Franch

  33. Slide 33: Major R&D Pipeline (SM/Vaccine)

    Major R&D Pipeline (SM/Vaccine) As of Jan 2019 Stage Generic Name/Project Code Number (Class) Target Indication Region Phase 1 Phase 2 Phase 3 NDA AF ASCA Edoxaban/DU-176b (Fxa inhibitor) VTE ASCA Very elderly patients AF JP Specialty medicine (SM) Prasugrel/CS-747 (anti-platelet agent) Ischemic str

  34. Slide 34: Out-licensing Projects

    Out-licensing Projects As of Jan 2019 Pre-clinical Phase 1 Phase 2  PLX7486 (Solid tumor / FMS/TRK inhibitor)  PLX8394 (Solid tumor / BRAF inhibitor) Oncology  PLX9486 (Solid tumor (gastrointestinal stromal tumor) / KIT inhibitor)  DS-1515  DS-2969  Laninamivir (Inflammatory disease / PI3Kδ in

  35. Slide 35: DS-8201: Poster at SABCS Efficacy comparison of 5.4・6.4mg/kg

    DS-8201: Poster at SABCS Efficacy comparison of 5.4・6.4mg/kg P1 Study: Best Percent Change in HER2- positive Breast Tumor Size from Baseline as Model-projected Event Rates for DS-8201 of April 18, 2018 Doses of 5.4 and 6.4 mg/kg ORR:52.6%(20/38) PFS:NR ORR:55.7%(34/61) PFS:16.4 M Based on the predic

  36. Slide 36: Abbreviations

    Abbreviations Abbreviation BTD Breakthrough therapy designation CR Complete response DCR Disease control rate DLT Dose limiting toxicity DOR Duration of response EGFR Epidermal growth factor receptor MTD Maximum tolerated dose NSCLC Non-small-cell lung cancer ORR Overall response rate Objective resp

  37. Slide 37: Contact address regarding this material

    Contact address regarding this material Daiichi Sankyo Co., Ltd. Corporate Communications Department TEL: +81-3-6225-1126 Email: [email protected]

Daiichi Sankyo Company — Q3 FY2018 Earnings Presentation on 6ix